Analysts at StockNews.com initiated coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) in a report issued on Saturday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Trading Down 0.2 %
Shares of NASDAQ:TTNP opened at $4.17 on Friday. Titan Pharmaceuticals has a 12 month low of $3.57 and a 12 month high of $14.80. The firm’s 50-day moving average is $4.98 and its 200 day moving average is $5.81.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last released its earnings results on Thursday, August 15th. The specialty pharmaceutical company reported ($2.29) EPS for the quarter.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
See Also
- Five stocks we like better than Titan Pharmaceuticals
- Do ETFs Pay Dividends? What You Need to Know
- Dot Ai IPO: CEO Ed Nabrotzky Shares Vision for Logistics Future
- How to Invest in the Best Canadian Stocks
- The Hottest Markets to Watch After the Fed’s 25 Bps Rate Cut
- What is the S&P/TSX Index?
- The Top 5 Performing S&P 500 Stocks YTD in 2024
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
